Bioneer A/S

What Bioneer A/S does

Bioneer A/S is a Danish Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) founded in 1982 and headquartered in Hørsholm within the Scion-DTU Science Park in Medicon Valley. The company operates a 3,350 m² facility comprising approximately 1,500 m² of laboratory space, supplemented by a 180 m² Bioneer:FARMA site co-located at the University of Copenhagen's Department of Pharmacy. Bioneer is a not-for-profit subsidiary of the Technical University of Denmark (DTU) and holds government-approved Research and Technology Organization (GTS) status under the Danish Ministry of Science and Technology.

The company delivers three integrated service lines: in vitro disease modelling (encompassing cancer/immuno-oncology, CNS, immunology, and iPSC-based platforms), drug formulation development, and recombinant protein R&D and manufacturing. Core proprietary technology platforms include the BION-CHO 6.0 System (CHO-DG44 mammalian expression achieving titers up to 6 g/L for monoclonal antibodies with stability over 60 generations), the BioSPHEER 3D cancer model platform (fibroblast/cancer cell spheroids mimicking tumor microenvironment), and proprietary license-free E. coli and Lactococcus lactis microbial expression systems. Capabilities are reinforced by LC-MS protein characterization, Ambr250 high-throughput bioreactors (capacity up to 2,000 L/year per product), high-density multi-electrode array (MEA) electrophysiology (26,400 measurement points per well), and iPSC reprogramming and CRISPR/TALEN gene editing.

Bioneer generates revenue through project-based, milestone-defined professional services contracts with biotech and pharmaceutical clients globally, supplemented by longer-term GMP manufacturing agreements for critical raw materials used in cell and gene therapy, diagnostics, and biosolutions. Customer acquisition is driven by direct enterprise sales via five dedicated business development managers and inside sales consultations, with a sales cycle characterized by free initial scoping, modular project design with Go/No-Go decision points, and direct scientist engagement. The firm reports supporting 300+ projects annually across nearly 20 countries for 100+ partners, and has completed 350+ recombinant protein projects to date, with named customers including Lundbeck, Johnson & Johnson, Takeda, Ymabs, and PanTarg.

Name

Bioneer A/S

Legal name

Bioneer A/S

Website

https://bioneer.dk

Company type

Private

Founded year

1982

Operating status

Operating

Headcount range

11–50 employees

Short description

Bioneer A/S is a Danish not-for-profit CRO/CDMO and DTU subsidiary providing in vitro disease modelling, drug formulation, and recombinant protein R&D and GMP manufacturing services to biotech and pharmaceutical companies globally, leveraging proprietary expression systems and iPSC-based disease models.

Ownership category

akta.pro rank

Product category

Contract Research and Manufacturing Services (CRO/CDMO)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Contract research organization
• Biopharmaceutical manufacturing
• Recombinant protein production
• In vitro disease modelling
• Drug formulation services

Headquarters

HQ city

Hørsholm

HQ country

Denmark

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. CRO Services - R&D and Testing: Contract research services including in vitro disease modelling, recombinant protein R&D services, and analytical characterization. Revenue is generated through project-based engagements with defined milestones, deliverables, and pricing. Services include cell line development, protein expression, purification, formulation, and assay development.
2. CDMO Services - GMP Manufacturing: Contract development and manufacturing services for GMP-grade proteins, including process development, manufacturing, and fill-finish services. Revenue generated through longer-term manufacturing agreements with pharmaceutical and biotech clients requiring critical raw materials for cell and gene therapy, diagnostics, and biosolutions.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Bioneer A/S is a Danish CRO/CDMO providing contract research and contract development & manufacturing services to biotech and pharmaceutical companies. Its core offerings span in vitro disease modelling (cancer, immuno-oncology, immunology, CNS, iPSC-based Parkinson's models), drug formulation development (Dynamic Gastric Model, biorelevant and cellular barrier models), and recombinant protein R&D and GMP manufacturing using proprietary mammalian (BION-CHO 6.0), E. coli, and Lactococcus lactis expression systems.

Product overview

Bioneer A/S is a Danish CRO/CDMO offering a comprehensive portfolio of life science services organized around three core pillars: In Vitro Modelling, Drug Formulation, and Recombinant Protein Development & Manufacturing. The In Vitro Modelling division includes disease-specific platforms such as the BioSPHEER™ 3D Cancer Model, Alpha-Synuclein Aggregation Assay, and Parkinson's Disease Models, complemented by technology services like High-density Multielectrode Arrays (MEA), High Content Imaging, and iPS Cell Reprogramming. The Drug Formulation services encompass Dynamic Gastric Model, biorelevant in-vitro models, and cellular barrier models. The Recombinant Protein services span from R&D (microbial and mammalian expression using proprietary systems like BION-CHO 6.0 System™, protein expression, purification, characterization, and upstream/downstream process development) through to GMP manufacturing of tailored proteins. The company recently expanded capabilities with LC-MS for enhanced protein characterization and the Ambr®250 high-throughput bioreactor system for accelerated upstream development. Bioneer operates from Medicon Valley in Denmark with a 40-year track record supporting biotech and pharmaceutical companies globally.

Differentiator

Problem solved

Functional benefit

Brands

• BioSPHEER™: 3D cancer model platform for preclinical drug discovery and cancer research
• BION-CHO 6.0 System™
• Bioneer E-c System™
• Bioneer Lactococcus lactis P170 System™

Products and services

• In Vitro Modelling Services Comprehensive in vitro disease modelling services covering cancer and immuno-oncology, immunology, CNS research, gene editing and reprogramming, and molecular histology for biotech and pharmaceutical drug discovery customers.
• BioSPHEER™ 3D Cancer Model In vitro 3D cancer platform offering tailored tumor models that simulate solid tumor complexity using spheroids composed of fibroblasts and cancer cells with extracellular matrix formation, supporting drug screening, mechanism-of-action studies, and tailored tumor model development.
• 3D Cancer Assays with xCELLigence® RTCA eSight Real-time cell analysis assays combining BioSPHEER™ 3D cancer models with eSight technology for continuous monitoring of tumor and immune cell behavior, interactions, and treatment responses.
• High-density Multielectrode Array (MEA) Assay High-density MEA assay service providing 26,400 measurement points per well for precise electrophysiological readouts of neuronal activity, network connectivity, and axonal signalling, with applications in disease modelling, drug discovery, toxicology, and phenotyping.
• Alpha-Synuclein Aggregation Assay FRET-based assay using human iPSC-derived dopaminergic or cortical neurons for investigating alpha-synuclein pathology in Parkinson's disease and related neurodegenerative disorders.
• Parkinson's Disease Models Human iPSC-based Parkinson's disease models capturing key mechanisms including alpha-synuclein aggregation, inflammation, and mitochondrial dysfunction for drug discovery and preclinical support.
• iPS Cell Reprogramming Reprogramming of patient cells (fibroblasts, PBMCs) into high-quality induced pluripotent stem cells using non-integrating methods for disease modelling and drug discovery.
• Drug Formulation Development Drug formulation development services including Dynamic Gastric Model, biorelevant in-vitro models, cellular barrier models, and formulation for peptides, proteins, and small molecules.
• Recombinant Proteins R&D Services Recombinant protein development services including expression in microbial and mammalian systems, upstream and downstream process development, purification, and characterization.
• Protein Expression Services and Strain Development Microbial protein expression services for E. coli and L. lactis, including parallel screening of up to 72 constructs, purified protein delivery in as little as 7 weeks, and gram-scale production.
• Characterization of Recombinant Proteins Comprehensive protein characterization using analytical techniques for purity, identity, structure, aggregation, and stability assessment across microbial and mammalian expression systems, enhanced by 2025 investment in LC-MS.
• Purification of Recombinant Proteins High-yield, high-purity protein purification using affinity, ion exchange, SEC, mixed mode chromatography, and endotoxin removal techniques achieving greater than 99% purity, built on more than 350 completed recombinant protein projects.
• Plasmid Preparation Large-scale plasmid amplification and preparation services (Maxi up to 1 mg, Mega up to 2.5 mg, Giga up to 10 mg) with endofree quality.
• Recombinant Proteins Manufacturing Manufacturing services for recombinant proteins including process development, GMP-grade protein manufacturing, and non-GMP manufacturing for microbial and mammalian systems, supported by 2025 acquisition of the Ambr®250 high-throughput bioreactor system.
• Tailored GMP Proteins Custom production of GMP-grade proteins for critical raw materials in pharma, biotech, and life science applications, including enzymes, affinity ligands, and growth factors for cell and gene therapies, with capacity up to 2,000 L per year per product.
• Human Alpha-Syn Fibrils Proprietary high-potency recombinant human alpha-synuclein fibrils for Parkinson's disease research, manufactured and QCed in-house with Certificate of Analysis.

Quantifiable outcome

• 300+ projects supported annually across nearly 20 countries
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Seven partnerships are on record, tiered core, minor and moderate.

• University of Copenhagen - Bioneer:FARMAcoreStrategic or Co-development Partner · 1 January 2007Established in 2007, Bioneer:FARMA is a collaborative site located at the Department of Pharmacy at the University of Copenhagen. The 180m2 facility includes offices and laboratories focused on pharmaceutical research and development. This partnership provides access to academic expertise and enhances research capabilities in drug delivery and formulation.
• Technical University of Denmark (DTU)coreStrategic or Co-development PartnerBioneer A/S is a subsidiary of DTU and is government-approved as an authorized Research and Technology Organization (GTS entity). DTU represents the ownership, and the partnership facilitates technology transfer and commercial application of scientific results. The GTS status connects technology and businesses in the Danish innovation system.
• DTU Science ParkminorStrategic or Co-development PartnerBioneer's headquarters is located in the Scion-DTU Science Park, facilitating innovation ecosystem connections and access to other biotech companies and research organizations in the Medicon Valley region.
• SymphogenminorStrategic or Co-development PartnerCollaboration through leadership recruitment, with CBO Jette Asboe Lassen having previously served as VP and Head of Business Development at Symphogen, a clinical stage oncology company developing antibody therapeutics.
• LundbeckmoderateStrategic or Co-development PartnerCNS research collaboration with over 100 publications in CNS research. Bioneer has collaborated with Lundbeck on Parkinson's disease models and related neurodegenerative disease research, contributing to the scientific foundation of Bioneer's CNS disease modelling capabilities.
• Johnson & JohnsonmoderateStrategic or Co-development PartnerCNS research collaboration with over 100 publications in CNS research. Bioneer has collaborated with Johnson & Johnson on Parkinson's disease models, contributing to understanding of alpha-synuclein aggregation and neurodegeneration mechanisms.
• Public/Private Funding ProgramsmoderateOthersBioneer participates in European Horizon, IHI - Innovative Health Initiative, Eurostars-EUREKA programs, and Danish research programs including Innovation Fund Denmark, Lundbeck Foundation, and Novo Nordisk Foundation for R&D collaboration projects.

Scale indicators8 records

Expansion highlights6 records

Direct peers

• Lonza: Lonza is the world's largest biologics CDMO, offering mammalian and microbial recombinant protein manufacturing, cell and gene therapy services, and integrated CMC support. Bioneer competes with Lonza in early-stage and difficult-to-express protein projects, though at a far smaller scale.
• AGC Biologics: AGC Biologics is a global CDMO specializing in mammalian and microbial biologics manufacturing, with a strong presence in Europe (Heidelberg, Copenhagen). It directly competes with Bioneer's CDMO services for recombinant protein clients; a Bioneer board member is a former AGC executive.
• Evotec: Evotec is a Germany-based contract research and CDMO organization offering integrated drug discovery, in vitro disease modelling, and biologics manufacturing. It competes with Bioneer across both its CRO and CDMO service lines, especially in CNS and iPSC-based discovery.
• Eurofins Discovery: Eurofins Discovery is the CRO arm of Eurofins Scientific, providing in vitro pharmacology, ADME, and custom assay services to biopharma. It overlaps with Bioneer's in vitro disease modelling, assay development, and recombinant protein services for biotech and pharma clients.
• Biovian: Biovian is a Nordic (Finland-based) CDMO offering GMP manufacturing for biologics, viral vectors, and microbial proteins. It is one of the closest size and geography matches to Bioneer, directly competing for European biotech and pharma CDMO contracts.
• Celonic Group: Celonic is a European CDMO specializing in mammalian and microbial biologics development and GMP manufacturing, including difficult-to-express proteins. It competes directly with Bioneer for recombinant protein CDMO projects.
• Ncardia: Ncardia is a European iPSC-focused CRO offering disease modelling, assay development, and cell-based screening services. It is a direct competitor to Bioneer's iPSC reprogramming and CNS disease modelling services for pharma discovery programs.
• Rentschler Biopharma: Rentschler Biopharma is a German-based, family-owned CDMO specializing in mammalian cell culture-based recombinant protein and antibody manufacturing. It competes with Bioneer for European biologics CDMO business, particularly in mAb and difficult-to-express proteins.

Broad incumbents

• Charles River Laboratories: Charles River is a global, full-service CRO/CDMO with broad capabilities across discovery, safety assessment, and biologics manufacturing. It competes with Bioneer for outsourced biopharma R&D budgets but at much greater scale and with a far broader service portfolio.
• Catalent: Catalent is a large global CDMO with biologics, cell and gene therapy, and fill-finish capabilities. It is a broad incumbent in the same biologics CDMO market as Bioneer, though operating at significantly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bioneer

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioneer A/S